SEC Comment Letter 0000000000-24-006287 to Cellectar Biosciences, Inc. (CLRB)
Cellectar Biosciences, Inc.
Date: May 31, 2024 · CIK: 0001279704 · Accession: 0000000000-24-006287
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279731
Letter
United States securities and exchange commission logo May 31, 2024 James V. Caruso President and Chief Executive Officer Cellectar Biosciences, Inc. 100 Campus Drive Florham Park, New Jersey 07932 Re:Cellectar Biosciences, Inc. Registration Statement on Form S-3 Filed May 24, 2024 File No. 333-279731 Dear James V. Caruso: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at 202-551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Asher M. Rubin, Esq.
Show Raw Text
United States securities and exchange commission logo
May 31, 2024
James V. Caruso
President and Chief Executive Officer
Cellectar Biosciences, Inc.
100 Campus Drive
Florham Park, New Jersey 07932
Re:Cellectar Biosciences, Inc.
Registration Statement on Form S-3
Filed May 24, 2024
File No. 333-279731
Dear James V. Caruso:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tim Buchmiller at 202-551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Asher M. Rubin, Esq.